[Skip to Navigation]
Comment & Response
April 2017

Caution in Generalizing the Use of Adjunctive Primary Corticosteroids in Kawasaki Disease to Unselected Non-Japanese Populations—Reply

Author Affiliations
  • 1Department of Pediatrics, Children's Hospital of Fudan University, Shanghai, China
  • 2Department of Cardiology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 3Department of Cardiology, Allgemein öffentliches Krankenhaus Elisabethinen, Linz, Austria
  • 4K. H. Elisabethinen Associated University Teaching Hospital of Medical University Innsbruck, Vienna, Austria
JAMA Pediatr. 2017;171(4):398-399. doi:10.1001/jamapediatrics.2016.5154

In Reply We thank García-Perdomo and Calle and Phuong et al for their comments regarding the interpretation of systematic reviews to better guide the treatment of Kawasaki disease (KD). Refractory KD resistant to the standard intravenous immunoglobulin treatment has been the focus of research on account of its high risk associated with coronary artery abnormalities (CAA).1,2 Novel adjunctive treatment modalities have increased during the past decade including corticosteroids.3

Add or change institution